# Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

> **NCT03524118** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 183 (actual)

## Conditions studied

- Respiratory Tract Infection
- Respiratory Syncytial Virus

## Interventions

- **DRUG:** Clesrovimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03524118
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2022-09-14
- **Final completion:** 2022-09-14
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524118, "Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03524118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*